Get started
MODERNA INCMODERNA INCMODERNA INC

MODERNA INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

MRNA trade ideas

MRNA8.18.21 MRNA: One of my students and I were having another unplanned mentoring session and follow-up on a futures trade. Then I asked her if she had looked at MRNA, and she hadn't, but she would have if she had had used alerts. It is important to use alerts to help you manage your time and your energy. On this video I will show you the sequence that my student and I went through from the first visit over a week ago... to this current time in the market: a "mini" mentoring session as she prepares to leave the nest to make some good money from the market.
NASDAQ:MRNA
by ScottBogatin
Moderna Analysis 18.08.2021Hello Traders, here is a full analysis for this asset. The entry will be taken only, if all rules of your trading plan are satisfied. Therefore I suggest you keep this pair on your watchlist and see if all of your rules are satisfied. Leave your thoughts in the comment section, I will reply to every single one of them. P.S. Tell me which asset you want me to break down next and I will cover it in my next analysis _____________________________________________________________________________________________________________________________________________________________________
NASDAQ:MRNA
by basictradingtv
2
MRNA. surely its a good RR short into earnings (with puts)MRNA is in absolute beast mode. I dont understand it. I know its market cap and i know its revenue and i know its one product. I understand anything can happen, even if its 2x overvalued it can still go up 2x more but i think its a good RR short into earnings tomorrow Will use 370 puts at current price of $2.80 at 3pm I think they are cheap given the potential Even if they beat earnings etc it could still go down due to the parabolic nature.of the pump .
NASDAQ:MRNAShort
by TheScalpman
8
Moderna: Can be a good time to buyThe Company will increase the number of participants in the study on the effectiveness of the vaccine on children between 6 months to 12 years old. In previous reports from the end of July, the company announced that 7,000 participants would participate in the study and now it is reported that following the FDA requirement, the company will increase the number of participants in the trial to 13,275. The company’s stock is down 15% in New York. Stock Price Target (Wall Street Journal) High $463.00 Median $271.50 Low $85.00 Average $290.83
NASDAQ:MRNALong
by JohnGoldman1